

Poster code: CO167

Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of the SPRINT trial versus a Natural History control arm

Ayo Adeyemi¹, Andrea M. Gross², Andrea Baldwin³, Eva Dombi², Brigitte C. Widemann², Kyaw Joe Sint¹

¹Health Economics and Outcomes Research, Alexion, AstraZeneca Rare Disease, Boston, MA, USA; ²Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; ³Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA

Supplementary Table 1. Baseline characteristics after propensity score analysis

	Propensity score analysis method								
	1:1 propensity score matching without replacement			IPTW			1:2 propensity score matching with replacement		
Characteristic	SPRINT (n=37)	NH (n=37)	Std difference	SPRINT (sum of weights =51.6)	NH (sum of weights =73.3)	Std difference	SPRINT (n=46)	NH (n=43)	Std difference
Sex, n (%)									
Female	15 (40.5)	14 (37.8)	0.055	22 (42.3)	28 (38.1)	0.086	19 (41.3)	14 (33.7)	0.158
Male	22 (59.5)	23 (62.2)		30 (57.7)	45 (61.9)		27 (58.7)	29 (66.3)	
Race, n (%)									
White	30 (81.1)	30 (81.1)	0.000	40 (77.1)	57 (78.4)	0.031	38 (82.6)	36 (82.6)	0.000
Other	7 (18.9)	7 (18.9)		12 (22.9)	16 (21.6)		8 (17.4)	7 (17.4)	
Age, years									
Median (min, max)	10.2 (4, 17)	10.9 (3, 17)	0.084	9.4 (4, 17)	9.8 (3, 18)	0.034	9.3 (4, 17)	9.7 (3, 18)	0.152
Weight, kg									
Median (min, max)	30.3 (16, 89)	29.5 (12, 78)	0.086	28.3 (16, 89)	29.8 (12, 78)	0.005	29.3 (16, 89)	26.8 (12, 78)	0.132
Height, cm									
Median (min, max)	136.0 (100,171)	131.7 (93, 180)	0.061	126.0 (100, 171)	131.0 (83, 180)	0.061	132.8 (100, 171)	130.8 (93, 180)	0.074
Target PN volume, mL									
Median (min, max)	478.0 (5.6, 3314)	433 (23.5, 5759)	0.149	478 (5.6, 3820)	422 (23.5, 5759)	0.034	480.5 (5.6, 3314)	427 (23.5, 5759)	0.178

	Propensity score analysis method								
	1:1 propensity score matching without replacement			IPTW			1:2 propensity score matching with replacement		
Characteristic	SPRINT (n=37)	NH (n=37)	Std difference	SPRINT (sum of weights =51.6)	NH (sum of weights =73.3)	Std difference	SPRINT (n=46)	NH (n=43)	Std difference
Target PN location, n (%)									
Head/neck/trunk	16 (43.2)	14 (37.8)	0.110	21 (39.8)	30 (40.5)	0.014	25 (54.3)	21 (48.9)	0.109
Trunk/extremity/ whole body	21 (56.8)	23 (62.2)		31 (60.2)	44 (59.5)		21 (45.7)	22 (51.1)	
PN status, n (%)									
Progressive	18 (48.6)	15 (40.5)	0.247	19 (37.0)	28 (37.8)	0.030	21 (45.7)	20 (45.7)	0.110
Non-progressive	15 (40.5)	15 (40.5)		24 (46.6)	34 (46.9)		15 (32.6)	13 (29.3)	
Unknown	4 (10.8)	7 (18.9)		8 (16.4)	11 (15.3)		10 (21.7)	11 (25.0)	

IPTW, inverse probability of treatment weighting; NH, Natural History; PN, plexiform neurofibroma.